http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 07:45:38 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Valion+Bio+notes+House+committee+directive+on+radiation+countermeasures/26632677.html <p>Valion Bio Inc. (NASDAQ: VBIO) said the U.S. House Armed Services Committee's fiscal 2027 National Defense Authorization Act report directs defense officials to develop a plan for prioritizing radiation and nuclear countermeasures that work both before and after exposure.</p><p>The committee's report instructs the Assistant Secretary of Defense for Nuclear Deterrence, Chemical, and Biological Defense Policy and Programs to coordinate with the Assistant Secretary of Defense for Health Affairs on creating a resources and fielding plan for these countermeasures.</p><p>The San Antonio-based biopharmaceutical company noted the directive follows its briefings to senior Department of Defense officials in April and May 2026 regarding http://www.streetinsider.com/Corporate+News/Valion+Bio+notes+House+committee+directive+on+radiation+countermeasures/26632677.html Thu, 11 Jun 2026 07:45:38 -0400 VBIO http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/Press+Releases/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html <div class="xn-content"> <p><i>Emanates from the FY27 NDAA process underway in the <span>U.S. Congress</span></i></p><p><i>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) </i></p><p><i><span>Follows Company's</span> two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("<span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio</span>" or the "Company") (f/k/a <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Tivic Health Systems, Inc.</span>), a late-stage biopharmaceutical company, confirmed today that the <span>U.S. House Armed Services Committee's</span> (the "Committee") FY27 National Defense Authorization Act ("NDAA") report directs the Assistant Secretary of Defense for http://www.streetinsider.com/PRNewswire/Valion+Bio+%28NASDAQ%3A+VBIO%29+Confirms+U.S.+House+Armed+Services+Committee+Initiative+to+Address+Urgent+Need+for+Radiation+Nuclear+Countermeasures/26632672.html Thu, 11 Jun 2026 07:45:00 -0400 A.06822034 A.60012002 O.20026344 O.52936745 O.69857460 VBIO http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Valion+Bio%2C+Inc.+++++++++++++++++++++/26611926.html si-local-file:///var/storage/secattach/20260605/26611926.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Valion+Bio%2C+Inc.+++++++++++++++++++++/26611926.html Fri, 05 Jun 2026 16:54:00 -0400 O.52936745 VBIO http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Valion+Bio%2C+Inc.+++++++++++++++++++++/26611926.html si-local-file:///var/storage/secattach/20260605/26611926.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Valion+Bio%2C+Inc.+++++++++++++++++++++/26611926.html Fri, 05 Jun 2026 16:54:00 -0400 O.52936745 VBIO http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Valion+Bio%2C+Inc.+++++++++++++++++++++/26611917.html si-local-file:///var/storage/secattach/20260605/26611917.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Valion+Bio%2C+Inc.+++++++++++++++++++++/26611917.html Fri, 05 Jun 2026 16:53:00 -0400 O.52936745 VBIO http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Valion+Bio%2C+Inc.+++++++++++++++++++++/26611917.html si-local-file:///var/storage/secattach/20260605/26611917.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Valion+Bio%2C+Inc.+++++++++++++++++++++/26611917.html Fri, 05 Jun 2026 16:53:00 -0400 O.52936745 VBIO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Valion+Bio%2C+Inc.++++++++++For%3A+May+28/26596412.html si-local-file:///var/storage/secattach/20260603/26596412.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Valion+Bio%2C+Inc.++++++++++For%3A+May+28/26596412.html Wed, 03 Jun 2026 09:00:00 -0400 O.52936745 VBIO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Valion+Bio%2C+Inc.++++++++++For%3A+May+28/26596412.html si-local-file:///var/storage/secattach/20260603/26596412.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Valion+Bio%2C+Inc.++++++++++For%3A+May+28/26596412.html Wed, 03 Jun 2026 09:00:00 -0400 O.52936745 VBIO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Valion+Bio%2C+Inc.++++++++++For%3A+May+18++Filed+by%3A+Handley+Michael+K/26529956.html si-local-file:///var/storage/secattach/20260520/26529956.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Valion+Bio%2C+Inc.++++++++++For%3A+May+18++Filed+by%3A+Handley+Michael+K/26529956.html Wed, 20 May 2026 19:52:00 -0400 O.52936745 VBIO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Valion+Bio%2C+Inc.++++++++++For%3A+May+18++Filed+by%3A+Handley+Michael+K/26529956.html si-local-file:///var/storage/secattach/20260520/26529956.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Valion+Bio%2C+Inc.++++++++++For%3A+May+18++Filed+by%3A+Handley+Michael+K/26529956.html Wed, 20 May 2026 19:52:00 -0400 O.52936745 VBIO http://www.streetinsider.com/Press+Releases/VALION+BIO+BRIEFS+SENIOR+DEPARTMENT+OF+WAR+AND+BARDA+OFFICIALS+IN+JOINT+ENGAGEMENT+ON+ENTOLIMOD+FOR+ACUTE+RADIATION+SYNDROME/26521975.html <div class="xn-content"> <p><i>Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>May 19, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute radiation syndrome (ARS) to senior officials from the <span value="ACORN:4095884156" idsrc="xmltag.org" >U.S. Department of War</span> and the <span value="ACORN:6001200261" idsrc="xmltag.org" >Biomedical Advanced Research and Development Authority</span> (BARDA) in a joint briefing held on <chron>May 14, 2026</chron>. The session was <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio's</span> second engagement with senior <span>Department of War</span> officials, following the Company's <chron>April 28, 2026</chron>, Pentagon briefing on http://www.streetinsider.com/Press+Releases/VALION+BIO+BRIEFS+SENIOR+DEPARTMENT+OF+WAR+AND+BARDA+OFFICIALS+IN+JOINT+ENGAGEMENT+ON+ENTOLIMOD+FOR+ACUTE+RADIATION+SYNDROME/26521975.html Tue, 19 May 2026 16:38:00 -0400 A.06822034 A.13522767 A.29922014 A.40958841 A.60012002 O.03289173 O.20026344 O.36670513 O.42081221 O.52936745 O.69857460 VBIO http://www.streetinsider.com/Press+Releases/VALION+BIO+BRIEFS+SENIOR+DEPARTMENT+OF+WAR+AND+BARDA+OFFICIALS+IN+JOINT+ENGAGEMENT+ON+ENTOLIMOD+FOR+ACUTE+RADIATION+SYNDROME/26521975.html <div class="xn-content"> <p><i>Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>May 19, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute radiation syndrome (ARS) to senior officials from the <span value="ACORN:4095884156" idsrc="xmltag.org" >U.S. Department of War</span> and the <span value="ACORN:6001200261" idsrc="xmltag.org" >Biomedical Advanced Research and Development Authority</span> (BARDA) in a joint briefing held on <chron>May 14, 2026</chron>. The session was <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio's</span> second engagement with senior <span>Department of War</span> officials, following the Company's <chron>April 28, 2026</chron>, Pentagon briefing on http://www.streetinsider.com/Press+Releases/VALION+BIO+BRIEFS+SENIOR+DEPARTMENT+OF+WAR+AND+BARDA+OFFICIALS+IN+JOINT+ENGAGEMENT+ON+ENTOLIMOD+FOR+ACUTE+RADIATION+SYNDROME/26521975.html Tue, 19 May 2026 16:38:00 -0400 A.06822034 A.13522767 A.29922014 A.40958841 A.60012002 O.03289173 O.20026344 O.36670513 O.42081221 O.52936745 O.69857460 VBIO http://www.streetinsider.com/Press+Releases/VALION+BIO+BRIEFS+SENIOR+DEPARTMENT+OF+WAR+AND+BARDA+OFFICIALS+IN+JOINT+ENGAGEMENT+ON+ENTOLIMOD+FOR+ACUTE+RADIATION+SYNDROME/26521975.html <div class="xn-content"> <p><i>Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>May 19, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute radiation syndrome (ARS) to senior officials from the <span value="ACORN:4095884156" idsrc="xmltag.org" >U.S. Department of War</span> and the <span value="ACORN:6001200261" idsrc="xmltag.org" >Biomedical Advanced Research and Development Authority</span> (BARDA) in a joint briefing held on <chron>May 14, 2026</chron>. The session was <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio's</span> second engagement with senior <span>Department of War</span> officials, following the Company's <chron>April 28, 2026</chron>, Pentagon briefing on http://www.streetinsider.com/Press+Releases/VALION+BIO+BRIEFS+SENIOR+DEPARTMENT+OF+WAR+AND+BARDA+OFFICIALS+IN+JOINT+ENGAGEMENT+ON+ENTOLIMOD+FOR+ACUTE+RADIATION+SYNDROME/26521975.html Tue, 19 May 2026 16:38:00 -0400 A.06822034 A.13522767 A.29922014 A.40958841 A.60012002 O.03289173 O.20026344 O.36670513 O.42081221 O.52936745 O.69857460 VBIO http://www.streetinsider.com/Press+Releases/VALION+BIO+BRIEFS+SENIOR+DEPARTMENT+OF+WAR+AND+BARDA+OFFICIALS+IN+JOINT+ENGAGEMENT+ON+ENTOLIMOD+FOR+ACUTE+RADIATION+SYNDROME/26521975.html <div class="xn-content"> <p><i>Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.sanant" idsrc="xmltag.org" >SAN ANTONIO</location></span>, <span class="legendSpanClass"><chron>May 19, 2026</chron></span> /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute radiation syndrome (ARS) to senior officials from the <span value="ACORN:4095884156" idsrc="xmltag.org" >U.S. Department of War</span> and the <span value="ACORN:6001200261" idsrc="xmltag.org" >Biomedical Advanced Research and Development Authority</span> (BARDA) in a joint briefing held on <chron>May 14, 2026</chron>. The session was <span value="NASDAQ-NMS:VBIO" idsrc="xmltag.org" >Valion Bio's</span> second engagement with senior <span>Department of War</span> officials, following the Company's <chron>April 28, 2026</chron>, Pentagon briefing on http://www.streetinsider.com/Press+Releases/VALION+BIO+BRIEFS+SENIOR+DEPARTMENT+OF+WAR+AND+BARDA+OFFICIALS+IN+JOINT+ENGAGEMENT+ON+ENTOLIMOD+FOR+ACUTE+RADIATION+SYNDROME/26521975.html Tue, 19 May 2026 16:38:00 -0400 A.06822034 A.13522767 A.29922014 A.40958841 A.60012002 O.03289173 O.20026344 O.36670513 O.42081221 O.52936745 O.69857460 VBIO